Qualigen Therapeutics Engages NFL Hall of Famer Mike Haynes as Advisor to the Company and Spokesman for the FastPack® Rapid Diagnostic System "Which Saved My Life"

CARLSBAD, Calif., July 7, 2020 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ("Qualigen" or the "Company") announces it has engaged Pro Football Hall of Fame and College Football Hall of Fame inductee Mike Haynes as an advisor to the Company and as spokesman for Qualigen's FastPack^® rapid diagnostic system.  After receiving an elevated PSA test result using a FastPack^® immunoassay test at a 2008 Hall of Fame event sponsored by Qualigen and the American Urological Association, Mr. Haynes has been a prominent advocate for prostate cancer testing.

Mr. Haynes will assist Qualigen's outreach efforts to support utilization and distribution of the FastPack^® system, as well as representing the Company at health events and with other sponsorship opportunities with the NFL and other U.S. professional sports leagues and organizations.

FastPack^® has been used worldwide for almost 20 years to assist in diagnosing many diseases, from elevated PSA levels and hormone deficiencies to other men's health conditions.  Qualigen also recently announced the launch of its reliable, rapid FastPack^® test for antibodies against the virus that causes COVID-19, slated for initial distribution this month.  

"I often tell people that Qualigen's FastPack^® testing system saved my life, and that is why I am thrilled to join the Qualigen team," stated Mike Haynes.  "FastPack^® is a reliable, convenient and rapid test system that gives physicians and other point-of-care medical professionals the power of large reference laboratory testing on location for their patients.  I recommend all men over the age of 55 to get a PSA test and know their family history. It's simple and an early diagnosis could save their lives too."

Mike Haynes starred for the New England Patriots and Los Angeles Raiders from 1976-1989.  Considered by some to be the greatest cornerback of all time, he was named to the NFL's 100^th Anniversary and 75^th Anniversary All-Time Teams.  In order to encourage men to know their prostate cancer risk and to get tested, Mr. Haynes has been a spokesperson for the Know Your Stats About Prostate Cancer® campaign, a combined effort between the NFL and the Urology Care Foundation, the official foundation of the American Urological Association.

"I've known Mike for many years and strongly support his message to inform men about the need to get tested for prostate cancer.  We welcome Mike to the Qualigen team and look forward to advancing the FastPack^® message together," stated Michael Poirier, President and Chief Executive Officer of Qualigen.   

About the FastPack^® System
The FastPack^® System is a rapid and highly accurate immunoassay testing system consisting of the FastPack^® Analyzer and the FastPack^® test pouch (a single-use, disposable, foil packet that includes the FastPack^® reagent chemistry). This "Laboratory in a Pouch" is installed in physician offices, clinics and small hospitals around the world, and quickly detects diseases and medical conditions at the point-of-care.  Since the conception of the system, the Company has expanded its assay menu to 10 tests including tests for prostate cancer, thyroid function, metabolic disorders, antibodies against SARS-CoV-2, and research applications. Over the past 20 years, FastPack^® has generated more than $100 million in commercial sales.  Qualigen's worldwide distributor for FastPack^® is Sekisui Diagnostics, LLC, a subsidiary of a multibillion-dollar Japanese chemical and technology company; Sekisui, in turn, works with national distributors including McKesson Corporation and Henry Schein Inc. 

About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as maintaining and expanding its core FDA-approved FastPack® System, which has been used successfully in diagnostics for almost 20 years. The FastPack® menu includes tests for cancer, men's health, hormone function, vitamin D status and antibodies against SARS-CoV-2. The Company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. The foundational aptamer of ALAN, AS1411, is also being studied for use in treating viral-based infectious diseases, including COVID-19.   RAS-F is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS™ is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. Qualigen's facility in Carlsbad, California is FDA and ISO Certified and its FastPack® product line is sold worldwide by its commercial partner Sekisui Diagnostics, LLC. For more information on Qualigen Therapeutics, Inc., please visit https://www.qualigeninc.com/.  

Qualigen Forward-Looking Statements
This news release contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company's judgment as of the date of this release. These statements include those related to potential future development, testing and launch of product candidates. Actual events or results may differ from our expectations. For example, there can be no assurance that advisor and advocacy efforts will improve FastPack sales; that adoption and placement of FastPack^® Pro System instruments (which are the only FastPack^® instruments on which the Company's SARS-CoV-2 IgG test kits can be run) will be widespread; that the Company will be able to manufacture the FastPack^® Pro System instruments and SARS-CoV-2 IgG test kits successfully; that any commercialization of the FastPack^® Pro System instruments and SARS-CoV-2 IgG test kits will be profitable; that the Company will successfully develop any drugs or therapeutic devices; that preclinical or clinical development of the Company's drugs or therapeutic devices will be successful; that future clinical trial data will be favorable or that such trials will confirm any improvements over other products or lack negative impacts; that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially successful; that the Company will be able to procure or earn sufficient working capital to complete the development, testing and launch of our prospective therapeutic products; or that we will be able to maintain or expand market demand and/or market share for our diagnostic products.  Our stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting the Company's business (including events beyond the Company's control, such as epidemics and resulting changes) can be found in the Company's prior filings with the Securities and Exchange Commission, available at www.sec.gov.  The Company disclaims any intent or obligation to update these forward-looking statements beyond the date of this news release, except as required by law. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

SOURCE Qualigen, Inc.

Related Links

http://www.qualigeninc.com